Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial

被引：231

作者：

Mugyenyi, P. ^{[3
]}

Walker, A. S. ^{[1
]}

Hakim, J. ^{[4
]}

Munderi, P. ^{[2
]}

Gibb, D. M. ^{[1
]}

Kityo, C. ^{[3
]}

Reid, A. ^{[4
]}

Grosskurth, H. ^{[2
]}

Darbyshire, J. H. ^{[1
]}

Ssali, F. ^{[3
]}

Bray, D. ^{[1
]}

Katabira, E. ^{[5
]}

Babiker, A. G.

Gilks, C. F.

Grosskurth, H. ^{[2
]}

Munderi, P. ^{[2
]}

Kabuye, G. ^{[2
]}

Nsibambi, D. ^{[2
]}

Kasirye, R. ^{[2
]}

Zalwango, E. ^{[2
]}

Nakazibwe, M. ^{[2
]}

Kikaire, B. ^{[2
]}

Nassuna, G. ^{[2
]}

Massa, R. ^{[2
]}

Fadhiru, K. ^{[2
]}

Namyalo, M. ^{[2
]}

Zalwango, A. ^{[2
]}

Generous, L. ^{[2
]}

Khauka, P. ^{[2
]}

Rutikarayo, N. ^{[2
]}

Nakahima, W. ^{[2
]}

Mugisha, A.

Todd, J.

Levin, J.

Muyingo, S.

Ruberantwari, A.

Kaleebu, P. ^{[2
]}

Yirrell, D. ^{[2
]}

Ndembi, N. ^{[2
]}

Lvagoba, F.

Hughes, P. ^{[2
]}

Aber, M. ^{[2
]}

Lara, A. Medina ^{[2
]}

Foster, S. ^{[2
]}

Amurwon, J. ^{[2
]}

Wakholi, B. Nyanzi ^{[2
]}

Whitworth, J. ^{[2
]}

Wangati, K. ^{[2
]}

Amuron, B. ^{[2
]}

Kajungu, D. ^{[2
]}

机构：

[1] MRC, Clin Trials Unit, London NW1 2DA, England

[2] MRC UVRI Uganda Res Unit AIDS, Entebbe, Uganda

[3] Joint Clin Res Ctr, Kampala, Uganda

[4] Univ Zimbabwe, Harare, Zimbabwe

[5] Makerere Univ, Mulago, Uganda

[6] Univ London Imperial Coll Sci Technol & Med, London, England

来源：

LANCET | 2010年 / 375卷 / 9709期

基金：

英国医学研究理事会;

关键词：

PUBLIC-HEALTH APPROACH; 5-YEAR OUTCOMES;

D O I：

10.1016/S0140-6736(09)62067-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background HIV antiretroviral therapy (ART) is often managed without routine laboratory monitoring in Africa; however, the effect of this approach is unknown. This trial investigated whether routine toxicity and efficacy monitoring of HIV-infected patients receiving ART had an important long-term effect on clinical outcomes in Africa. Methods In this open, non-inferiority trial in three centres in Uganda and one in Zimbabwe, 3321 symptomatic, ART-naive, HIV-infected adults with CD4 counts less than 200 cells per mu L starting ART were randomly assigned to laboratory and clinical monitoring (LCM; n=1659) or clinically driven monitoring (CDM; n=1662) by a computer-generated list. Haematology, biochemistry, and CD4-cell counts were done every 12 weeks. In the LCM group, results were available to clinicians; in the CDM group, results (apart from CD4-cell count) could be requested if clinically indicated and grade 4 toxicities were available. Participants switched to second-line ART after new or recurrent WHO stage 4 events in both groups, or CD4 count less than 100 cells per mu L (LCM only). Co-primary endpoints were new WHO stage 4 HIV events or death, and serious adverse events. Non-inferiority was defined as the upper 95% confidence limit for the hazard ratio (HR) for new WHO stage 4 events or death being no greater than 1.18. Analyses were by intention to treat. This study is registered, number ISRCTN13968779. Findings Two participants assigned to CDM and three to LCM were excluded from analyses. 5-year survival was 87% (95% CI 85-88) in the CDM group and 90% (88-91) in the LCM group, and 122 (7%) and 112 (7%) participants, respectively, were lost to follow-up over median 4.9 years' follow-up. 459 (28%) participants receiving CDM versus 356 (21%) LCM had a new WHO stage 4 event or died (6.94 [95% CI 6.33-7.60] vs 5.24 [4.72-5.81] per 100 person-years; absolute difference 1.70 per 100 person-years [0.87-2.54]; HR 1.31 [1.14-1.51]; p=0.0001). Differences in disease progression occurred from the third year on ART, whereas higher rates of switch to second-line treatment occurred in LCM from the second year. 283 (17%) participants receiving CDM versus 260 (16%) LCM had a new serious adverse event (HR 1.12 [0.94-1.32]; p=0.19), with anaemia the most common (76 vs 61 cases). Interpretation ART can be delivered safely without routine laboratory monitoring for toxic effects, but differences in disease progression suggest a role for monitoring of CD4-cell count from the second year of ART to guide the switch to second-line treatment. Funding UK Medical Research Council, the UK Department for International Development, the Rockefeller Foundation, GlaxoSmithKline, Gilead Sciences, Boehringer-Ingelheim, and Abbott Laboratories.

引用

页码：123 / 131

页数：9

共 24 条

[11] The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy [J].

Hosseinipour, Mina C. ;

van Oosterhout, Joep J. G. ;

Weigel, Ralf ;

Phiri, Sam ;

Kamwendo, Debbie ;

Parkin, Neil ;

Fiscus, Susan A. ;

Nelson, Julie A. E. ;

Eron, Joseph J. ;

Kumwenda, Johnstone .

AIDS, 2009, 23 (09) :1127-1134

[12] Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa [J].

Kaleebu, P. ;

Pillay, D. ;

Walker, A. S. ;

Robertson, V. ;

Gale, C. V. ;

Enzama, R. ;

Yirrell, D. ;

Lyagoba, F. ;

Kityo, C. ;

Munderi, P. ;

Reid, A. ;

Gibb, D. M. ;

Bray, D. ;

Burke, A. ;

Ait-Khaled, M. ;

Darbyshire, J. H. ;

Muygenyi, P. ;

Hakim, J. ;

Grosskurth, H. ;

Gilks, C. ;

Enzama, R. ;

Tugume, S. ;

Chirara, M. ;

Lyagoba, F. ;

Gale, C. ;

Mugyenyi, P. ;

Kityo, C. ;

Ssali, F. ;

Tumukunde, D. ;

Otim, T. ;

Namale, L. ;

Mukose, A. ;

Muhwezi, A. ;

Kabuye, G. ;

Mulindwa, G. ;

Atwine, D. ;

Kyomugisha, H. ;

Drasiku, A. ;

Tumusiime, C. ;

Sabiiti, J. ;

Zawedde, C. ;

Komugyena, J. ;

Okiror, J. ;

Byaruhanga, R. ;

Ocitti, P. ;

Grace, T. Bakainyaga ;

Katabira, H. ;

Barungi, G. ;

Masiira, D. ;

Atwine, A. .

AIDS, 2006, 20 (10) :1391-1399

[13] Misclassification of First-Line Antiretroviral Treatment Failure Based on Immunological Monitoring of HIV Infection in Resource-Limited Settings [J].

Kantor, Rami ;

Diero, Lameck ;

DeLong, Allison ;

Kamle, Lydia ;

Muyonga, Sarah ;

Mambo, Fidelis ;

Walumbe, Eunice ;

Emonyi, Wilfred ;

Chan, Philip ;

Carter, E. Jane ;

Hogan, Joseph ;

Buziba, Nathan .

CLINICAL INFECTIOUS DISEASES, 2009, 49 (03) :454-462

[14]

LARA AM, 2009, 5 IAS C HIV PATH TRE

[15] Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa [J].

Lawn, Stephen D. ;

Little, Francesca ;

Bekker, Linda-Gail ;

Kaplan, Richard ;

Campbel, Elizabeth ;

Orrell, Catherine ;

Wood, Robin .

AIDS, 2009, 23 (03) :335-342

[16] 5-Year Survival of Patients with AIDS Receiving Antiretroviral Therapy in Haiti [J].

Leger, Paul ;

Charles, Macarthur ;

Severe, Patrice ;

Riviere, Cynthia ;

Pape, Jean William ;

Fitzgerald, Daniel W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (08) :828-829

[17] Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy:: a randomized double-blind trial (NORA) [J].

Munderi, P. ;

Team, Dart Trial ;

Kityo, C. ;

Walker, A. S. ;

Gilks, C. ;

Gibb, D. M. ;

Ssali, F. ;

Babiker, A. G. ;

Reid, A. ;

Bray, D. ;

Darbyshire, J. H. ;

Grosskurth, H. ;

Mugyenyi, P. .

TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2008, 13 (01) :6-16

[18]

Munderi P, 2006, 16 INT AIDS C TOR CA

[19] DESIGN AND ANALYSIS OF RANDOMIZED CLINICAL-TRIALS REQUIRING PROLONGED OBSERVATION OF EACH PATIENT .1. INTRODUCTION AND DESIGN [J].

PETO, R ;

PIKE, MC ;

ARMITAGE, P ;

BRESLOW, NE ;

COX, DR ;

HOWARD, SV ;

MANTEL, N ;

MCPHERSON, K ;

PETO, J ;

SMITH, PG .

BRITISH JOURNAL OF CANCER, 1976, 34 (06) :585-612

[20] Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model [J].

Phillips, Andrew N. ;

Pillay, Deenan ;

Miners, Alec H. ;

Bennett, Diane E. ;

Gilks, Charles F. ;

Lundgren, Jens D. .

LANCET, 2008, 371 (9622) :1443-1451

← 1 2 3 →